Shore Capital Reaffirms Buy Rating for Primary Health Properties (LON:PHP)

Shore Capital restated their buy rating on shares of Primary Health Properties (LON:PHPFree Report) in a research note published on Wednesday morning, MarketBeat.com reports.

Separately, Berenberg Bank upped their price objective on Primary Health Properties from GBX 103 ($1.34) to GBX 110 ($1.44) and gave the company a “buy” rating in a report on Wednesday, September 18th.

Get Our Latest Stock Analysis on PHP

Primary Health Properties Price Performance

Primary Health Properties stock opened at GBX 99.05 ($1.29) on Wednesday. The company has a debt-to-equity ratio of 96.98, a quick ratio of 0.62 and a current ratio of 0.48. Primary Health Properties has a 52 week low of GBX 84.20 ($1.10) and a 52 week high of GBX 109 ($1.42). The firm has a market cap of £1.33 billion, a P/E ratio of -9,905.00, a P/E/G ratio of 5.64 and a beta of 0.41. The business’s fifty day moving average is GBX 99.19 and its two-hundred day moving average is GBX 95.17.

Primary Health Properties Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, November 22nd. Investors of record on Thursday, October 10th will be issued a dividend of GBX 1.73 ($0.02) per share. The ex-dividend date of this dividend is Thursday, October 10th. This represents a dividend yield of 1.71%. Primary Health Properties’s payout ratio is presently -70,000.00%.

About Primary Health Properties

(Get Free Report)

Primary Health Properties (PHP) is the leading investor in modern healthcare properties in the UK & Ireland. PHP is a UK based Real Estate Investment Trust (REIT) with a clear objective to create progressive returns to shareholders through a combination of earnings growth and capital appreciation.

Featured Articles

Receive News & Ratings for Primary Health Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Primary Health Properties and related companies with MarketBeat.com's FREE daily email newsletter.